GLMD Stock Catalyst: Galmed Pharmaceuticals Ltd. Announces Breakthrough Development of Aramchol for Parkinson's Disease

Jul 28, 2026 · 7:00am ET

The company targets a $6 billion market with its new formulation.

Max move

+32.4%

High of day $5.36

Sparker timei

7:00am ET

GLMD · Jul 28, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced the breakthrough development of a Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease. This new formulation aims to address the unmet needs in the treatment of Parkinson's Disease.

The company is targeting a $6 billion market with this innovative approach. The development represents a significant step forward in Galmed's mission to bring novel therapeutics to patients suffering from this debilitating condition.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GLMD sparks.

Download Sniper App →

Catch the next GLMD-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →